Real-world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. (RAVEN)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/50480
• EU PAS number:
  EUPAS43571
• Study ID:
  50480
• Official title and acronym:
  Real-world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. (RAVEN)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This is a retrospective cohort study to assess the real world effectiveness of the Oxford/AstraZeneca COVID-19 vaccine in England. The study is using linkage of the English national databases on COVID-19 vaccination, testing, medical records, hospitalization, and death. The analysis will primarily look at both doses, though the study will also report on single dose and booster doses.
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Actual: 21/05/2021

Study start date

Actual: 23/08/2021

Data analysis start date

Actual: 06/09/2021

Date of final study report

Planned: 25/01/2023

Actual: 20/07/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca

Study protocol

Initial protocol

D8111R00007-csp-v1_Redacted2

Updated protocol

d8111r00007-csp-v3_Redacted

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

D8111R00007